GSK-1070916 (GMP)
GSK-1070916 (GMP) is GSK-1070916 produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with Kis of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A[1][2].
Product Specifications
CAS Number
942918-07-2
Product Name Alternative
GSK-1070916A (GMP)
UNSPSC
12352005
Target
Apoptosis; Aurora Kinase
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Field of Research
Cancer
Smiles
O=C(NC1=CC=C(C2=NN(C=C2C3=C4C(NC(C5=CC=CC(CN(C)C)=C5)=C4)=NC=C3)CC)C=C1)N(C)C
Molecular Formula
C30H33N7O
Molecular Weight
507.63
References & Citations
[1]Adams ND, et al. Discovery of GSK-1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53 (10) :3973-4001.|[2]Hardwicke MA, et al. GSK-1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther. 2009 Jul;8 (7) :1808-17.
Shipping Conditions
Room temperature
Scientific Category
GMP Small Molecules
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400257-100 1x 100 µL
Cytokeratin, HMW (AE-3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470253-500 1x 500 µL
Cytokeratin, LMW (AE-1), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 